Zimbabwe has declined a substantial American health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's demand for confidential biological samples.
This rejection became public after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative has since stated that the US was seeking health data for scientific study and commercial gain while refused to share the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for more negotiations to secure a agreement suitable to both sides so the country's critical HIV programme can continue.
Broader Implications
Zimbabwe's decision follows a comparable case in Kenya, where a high court halted a similar deal with the US after concerns were raised about the security of Kenyans' medical information.
After resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
Based on reports, Sixteen nations in Africa have to date signed similar health pacts, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research without any assurance that the final treatments would be accessible to our citizens should a new health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the American exit from the global health body and its push of one-on-one health agreements were undermining structures already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This framework is intended to guarantee that when a nation provides its information, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We encourage further discussions with our US partners on how future co-operation could be arranged in a way that respects the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but recommended that negotiations should continue considering much of the nation's Aids initiatives relied on external financing.
"If specific concerns exist, such as those involving data governance or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal highlights the ongoing tensions between receiving crucial international aid and safeguarding national sovereignty in an increasingly data-driven world.